iData Insights

COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands Now Available at iData Insights

Press Release   •   Jan 02, 2016 14:49 IST

COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands Summary Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression. There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease. Scope The COPD market has benefited from notable additions over recent years. - Which classes of drug dominate the market? - What additional benefits have newly approved therapies brought to market? - How do the leading marketed therapies compare clinically? The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies. - Which molecular targets appear most frequently in the pipeline? - How will the new therapies be positioned in the treatment of COPD? - How have selected late-stage pipeline therapies performed in clinical trials? COPD clinical trials have an overall attrition rate of 89.6%. - What are the failure rates for individual Phases of clinical development? - How do COPD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages? The COPD market is forecast to rise from a value of $9.2 billion in 2014 to $11.2 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed. - How much of a role will disease prevalence and new product approvals play in market growth? - Will generic competition have a significant impact on the market over the forecast period? There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006. - Which territories show the most deal activity? - What were the trends in deal completion by product stage of development? - What were the conditions of the key licensing or co-development deals to take place in COPD? Reasons to buy This report will allow you to - - Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD. - Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data. - Analyze the COPD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast. - Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value. - Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=161109/copd-therapeutics-in-major-developed-markets-to-2021-emergence-of-addition-in-class-and-first-in-class-products-offsets-sales-erosion-of-leading-brands

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=161109/copd-therapeutics-in-major-developed-markets-to-2021-emergence-of-addition-in-class-and-first-in-class-products-offsets-sales-erosion-of-leading-brands

Table of Contents

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 9

2.1 Disease Introduction 9

2.2 Symptoms 9

2.3 Etiology 9

2.4 Pathophysiology 10

2.5 Diagnosis 10

2.6 Assessment of Disease Severity 11

2.7 Treatment 12

2.8 Treatment Algorithm 14

2.8.1 Mild COPD 14

2.8.2 Moderate-to-Severe COPD 15

2.8.3 Very Severe COPD 16

2.8.4 Marketed Products Heat Map 17

3 Marketed Products 21

3.1 Product Profiles 22

3.1.1 Bronchodilator and Inhaled Corticosteroid Combination Therapy 22

3.1.2 Bronchodilator Monotherapy 24

3.1.3 Bronchodilator Combination Therapy 28

3.1.4 Alternative Therapy 30

3.1.5 Conclusion 31

3.1.6 Unmet Needs 32

4 COPD Pipeline 33

4.1 Molecular Target Analysis 35

4.2 Clinical Trials 40

4.2.1 Failure Rate 40

4.2.2 Clinical Trial Duration 42

4.2.3 Clinical Trial Size 44

4.2.4 Comparative Clinical Trial Metrics Analysis 48

4.3 Promising Pipeline Molecules 49

4.3.1 Mepolizumab - GSK 49

4.3.2 Vilanterol Trifenatate - GSK/Theravance 50

4.3.3 Fluticasone Furoate + Umeclidinium Bromide + Vilanterol Trifenatate - GSK 51

4.3.4 Budesonide + Formoterol Fumarate + Glycopyrronium (PT010) - AstraZeneca/Pearl Therapeutics 53

4.3.5 Glycopyrronium + Formoterol Fumarate (PT003) - AstraZeneca/Pearl Therapeutics 54

4.3.6 Glycopyrronium + Formoterol Fumarate Forecast 55

4.3.7 Benralizumab - AstraZeneca/MedImmune 56

4.3.8 TD-4208 - Theravance 57

4.3.9 Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium - Chiesi Farmaceutici 59

4.3.10 Heat Map for Pipeline Products 61

5 Market Forecast to 2021 63

5.1 Global Market 64

5.2 North America 66

5.2.1 Treatment Usage Patterns 66

5.2.2 Annual Cost of Therapy 67

5.2.3 Market Size 69

5.3 Top Five EU Markets 70

5.3.1 Treatment Usage Patterns 70

5.3.2 Annual Cost of Therapy 72

5.3.3 Market Size 73

5.4 Japan 75

5.4.1 Treatment Usage Patterns 75

5.4.2 Annual Cost of Therapy 75

5.4.3 Market Size 76

5.5 Drivers and Barriers for the COPD market 77

5.5.1 Drivers 77

5.5.2 Barriers 78

6 Deals and Strategic Consolidations 79

6.1 Licensing Deals 79

6.1.1 AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 84

6.1.2 Evotec Enters into Licensing Agreement with Zhejiang Conba for EVT 401 84

6.1.3 Vectura Enters into Licensing Agreement with International Pharma Company for VR315 85

6.1.4 Almirall Enters into Licensing Agreement with Kyorin for Aclidinium Bromide 85

6.1.5 Pulmagen Therapeutics Enters into Research and Licensing Agreement with AstraZeneca 85

6.2 Co-development Deals 85

6.2.1 Theravance Enters into Development and Commercialization Agreement with Mylan 90

6.2.2 Five Prime Therapeutics Expands Co-Development Agreement with GSK 90

6.2.3 Galapagos Enters into Strategic Alliance with Roche 91

6.2.4 Forest Laboratories Enters into Agreement with Almirall 91

6.2.5 Forest Laboratories Enters into Co-Development Agreement with Nycomed 91

7 Appendix 92

7.1 All Pipeline Drugs by Phase 92

7.1.1 Discovery 92

7.1.2 Preclinical 94

7.1.3 Phase I 99

7.1.4 Phase II 101

7.1.5 Phase III 104

7.1.6 Filed 106

7.2 Market Forecasts to 2021 106

7.2.1 Global 106

7.2.2 US 106

7.2.3 Canada 107

7.2.4 UK 107

7.2.5 France 108

7.2.6 Germany 108

7.2.7 Italy 109

7.2.8 Spain 109

7.2.9 Japan 110

7.3 Bibiography 110

7.4 Abbreviations 117

7.5 Research Methodology 118

7.5.1 Secondary Research 119

7.5.2 Marketed Product Profiles 119

7.5.3 Late-Stage Pipeline Candidates 119

7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 119

7.5.5 Forecasting Model 120

7.5.6 Deals Data Analysis 121

7.6 Expert Panel Validation 122

7.7 Contact Us 122

7.8 Disclaimer 122

Read More http://www.idatainsights.com/reports-landing-page.php?id=161109/copd-therapeutics-in-major-developed-markets-to-2021-emergence-of-addition-in-class-and-first-in-class-products-offsets-sales-erosion-of-leading-brands

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects